Acitretin in dermatology: A review

Journal of Drugs in Dermatology

Volumn 10, Issue 7, 2011, Pages 772-782

  Dunn, Lauren K ^a   Gaar, Laini R ^a   Yentzer, Brad A ^a   O'Neill, Jenna L ^a   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; CALCIPOTRIOL; CYCLOSPORIN; ETANERCEPT; ETRETIN; ETRETINATE; GEMFIBROZIL; HYDROXYCHLOROQUINE; INFLIXIMAB; LIPID; LIVER ENZYME; METHOTREXATE; PIOGLITAZONE; PLACEBO; PSORALEN; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; TRIACYLGLYCEROL;

ALOPECIA; BELL PALSY; BLEPHARITIS; BRAIN PSEUDOTUMOR; CHEILITIS; CHEMOPROPHYLAXIS; CORNEA DISEASE; DARIER DISEASE; DEPRESSION; DIABETES MELLITUS; DIET RESTRICTION; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRY LIP; DRY SKIN; FOOD AND DRUG ADMINISTRATION; GENETIC TRANSCRIPTION; HEPATITIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERKERATOSIS; HYPERLIPIDEMIA; HYPEROSTOSIS; HYPERTRANSAMINASEMIA; INFLAMMATORY DISEASE; LEUKOPLAKIA; LICHEN PLANUS; LICHEN SCLEROSUS ET ATROPHICUS; LIP DISEASE; LIPID BLOOD LEVEL; LIVER TOXICITY; LOW DRUG DOSE; MONOTHERAPY; NAIL DISEASE; PHOTOTHERAPY; PITYRIASIS RUBRA PILARIS; PRURITUS; PSORIASIS; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; PUSTULAR PSORIASIS; PUSTULOSIS PALMOPLANTARIS; PUVA; RETINOL INTOXICATION; REVIEW; RHINITIS; SIDE EFFECT; SKIN CANCER; SKIN DISEASE; SKIN LUPUS ERYTHEMATOSUS; SQUAMOUS CELL CARCINOMA; TERATOGENICITY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; XEROPHTHALMIA; XEROSTOMIA;

ACITRETIN; HUMANS; KERATOLYTIC AGENTS; OFF-LABEL USE; PSORIASIS; SKIN DISEASES; SKIN NEOPLASMS;

EID: 80053085387     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Lucek RW, Colburn WA. Clinical pharmacokinetics of the retinoids. Clin Pharmacokinet. 1985;10(1):38-62. (Pubitemid 15198240)
2. Vahlquist A, Rollman O, Pihl-Lundin I. Tissue distribution of aromatic retinoid (etretinate) in three autopsy cases: Drug accumulation in adrenals and fat. Acta Derm Venereol. 1986;66(5):431-434. (Pubitemid 17170766)
3. DiGiovanna JJ, Zech LA, Ruddel ME, et al. Etretinate. Persistent serum levels after long-term therapy. Arch Dermatol. 1989;125(2):246-251. (Pubitemid 19070213)
4. Wolverton SE. Comprehensive Dermatologic Drug Therapy. Philadelphia, PA: Saunders Elsevier; 2007.
5. Blanchet-Bardon C, Nazzaro V, Rognin C, et al. Acitretin in the treatment of severe disorders of keratinization. Results of an open study. J Am Acad Dermatol. 1991;24(6 Pt 1):982-986.
6. De Jong EM, Van De Kerkhof PC. Coexistence of palmoplantar lichen planus and lupus erythematosus with response to treatment using acitretin. Br J Dermatol. 1996;134(3):538-541. (Pubitemid 26090950)
7. Wiegand UW, Chou RC. Pharmacokinetics of acitretin and etretinate. J Am Acad Dermatol. 1998;39(2 Pt 3):25S-33S.
8. Brindley CJ, Dubach UC, Forgo I. Absolute bioavailability of acitretin (Ro 10-1670). In: Reichert U, Shroot B, eds. Pharmacology of Retinoids in the Skin. Basel: Karger; 1989. p. 207-210.
9. Koo J. Systemic sequential therapy of psoriasis: A new paradigm for improved therapeutic results. J Am Acad Dermatol. 1999;41(3 Pt 2):25S-28S.
10. Laugier JP, de SG, Bun H, et al. Acitretin biotransformation into etretinate: Role of ethanol on in vitro hepatic metabolism. Dermatology. 1994;188(2):122-125.
11. Larsen FG, Jakobsen P, Knudsen J, et al. Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J Invest Dermatol. 1993;100(5):623-627. (Pubitemid 23128356)
12. Gronhoj LF, Steinkjer B, Jakobsen P, et al. Acitretin is converted to etretinate only during concomitant alcohol intake. Br J Dermatol. 2000;143(6):1164-1169. (Pubitemid 32052750)
13. Maier H, Honigsmann H. Assessment of acitretin-treated female patients of childbearing age and subsequent risk of teratogenicity. Br J Dermatol. 2001;145(6):1028-1029. (Pubitemid 34204487)
14. Orfanos CE, Zouboulis CC, mond-Roesler B, et al. Current use and future potential role of retinoids in dermatology. Drugs. 1997;53(3):358-388. (Pubitemid 27117359)
15. Warren RB, Griffiths CE. Systemic therapies for psoriasis: Methotrexate, retinoids, and cyclosporine. Clin Dermatol. 2008;26(5):438-447.
16. Werner B, Bresch M, Brenner FM, et al. Comparative study of histopathological and immunohistochemical findings in skin biopsies from patients with psoriasis before and after treatment with acitretin. J Cutan Pathol. 2008;35(3):302-310. (Pubitemid 351171246)
17. Pearce DJ, Lucas J, Wood B, et al. Death from psoriasis: Representative US data. J Dermatolog Treat. 2006;17(5):302-303. (Pubitemid 44595019)
18. Al-Kudwah AJ, Feldman SR. Management of Psoriasis. South Med J. 2009;102(6):631-636.
19. Magis NL, Blummel JJ, Kerkhof PC, et al. The treatment of psoriasis with etretinate and acitretin: A follow up of actual use. Eur J Dermatol. 2000;10(7):517-521.
20. Olsen EA, Weed WW, Meyer CJ, et al. A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis. J Am Acad Dermatol. 1989;21(4 Pt 1):681-686. (Pubitemid 19251725)
21. Kragballe K, Jansen CT, Geiger JM, et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study. Acta Derm Venereol. 1989;69(1):35-40. (Pubitemid 19028329)
22. Van De Kerkhof PC. Update on retinoid therapy of psoriasis in: An update on the use of retinoids in dermatology. Dermatol Ther. 2006;19(5):252-263. (Pubitemid 44470109)
23. Buccheri L, Katchen BR, Karter AJ, et al. Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection. Arch Dermatol. 1997;133(6):711-715. (Pubitemid 27263704)
24. Tosti A, Ricotti C, Romanelli P, et al. Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol. 2009;145(3):269-271.
25. Goldfarb MT, Ellis CN, Gupta AK, et al. Acitretin improves psoriasis in a dose-dependent fashion. J Am Acad Dermatol. 1988;18(4 Pt 1):655-662.
26. Pearce DJ, Klinger S, Ziel KK, et al. Low-dose acitretin is associated with fewer adverse events than high-dose acitretin in the treatment of psoriasis. Arch Dermatol. 2006;142(8):1000-1004. (Pubitemid 44268476)
27. Rim JH, Park JY, Choe YB, et al. The efficacy of calcipotriol + acitretin combination therapy for psoriasis: Comparison with acitretin monotherapy. Am J Clin Dermatol. 2003;4(7):507-510. (Pubitemid 36871768)
28. Van De Kerkhof PC, Cambazard F, Hutchinson PE, et al. The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis. Br J Dermatol. 1998;138(1):84-89. (Pubitemid 28077942)
29. Ezquerra GM, Regana MS, Millet PU. Combination of acitretin and oral calcitriol for treatment of plaque-type psoriasis. Acta Derm Venereol. 2007;87(5):449-450. (Pubitemid 351373434)
30. Vanderveen EE, Ellis CN, Campbell JP, et al. Methotrexate and etretinate as concurrent therapies in severe psoriasis. Arch Dermatol. 1982;118(9):660-662. (Pubitemid 12061439)
31. Adams JD. Concurrent methotrexate and etretinate therapy for psoriasis. Arch Dermatol. 1983;119(10):793.
32. Rosenbaum MM, Roenigk HH, Jr. Treatment of generalized pustular psoriasis with etretinate (Ro 10-9359) and methotrexate. J Am Acad Dermatol. 1984;10(2 Pt 2):357-361. (Pubitemid 14181965)
33. Tuyp E, MacKie RM. Combination therapy for psoriasis with methotrexate and etretinate. J Am Acad Dermatol. 1986;14(1):70-73. (Pubitemid 16137930)
34. Larsen FG, Nielsen-Kudsk F, Jakobsen P, et al. Interaction of etretinate with methotrexate pharmacokinetics in psoriatic patients. J Clin Pharmacol. 1990;30(9):802-807. (Pubitemid 20334340)
35. Soriatane® (acitretin) prescribing information. Stiefel Laboratories, Inc. Available at: http://www.stiefel.com/us/US-Soriatane-Capsules.pdf. Accessed July 1, 2009.
36. Lowenthal KE, Horn PJ, Kalb RE. Concurrent use of methotrexate and acitretin revisited. J Dermatolog Treat. 2008;19(1):22-26. (Pubitemid 351252717)
37. Gisondi P, Del GM, Cotena C, et al. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: A 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol. 2008;158(6):1345-1349. (Pubitemid 351692891)
38. Smith EC, Riddle C, Menter MA, et al. Combining systemic retinoids with biologic agents for moderate to severe psoriasis. Int J Dermatol. 2008;47(5):514-518. (Pubitemid 351560322)
39. Langewouters AM, Van Erp PE, De Jong EM, et al. The added therapeutic efficacy and safety of alefacept in combination with other (systemic) anti-psoriatics in refractory psoriasis. J Dermatolog Treat. 2006;17(6):362-369. (Pubitemid 46895584)
40. Mittal R, Malhotra S, Pandhi P, et al. Efficacy and safety of combination Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: A randomized, double-blind, placebo-controlled clinical trial. Arch Dermatol. 2009;145(4):387-393.
41. Ruzicka T, Sommerburg C, Braun-Falco O, et al. Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis. Arch Dermatol. 1990;126(4):482-486. (Pubitemid 20128961)
42. Lowe NJ, Prystowsky JH, Bourget T, et al. Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol. 1991;24(4):591-594.
43. Tanew A, Guggenbichler A, Honigsmann H, et al. Photochemotherapy for severe psoriasis without or in combination with acitretin: A randomized, double-blind comparison study. J Am Acad Dermatol. 1991;25(4):682-684.
44. Ozdemir M, Engin B, Baysal I, et al. A randomized comparison of acitretin-narrow-band TL-01 phototherapy and acitretin-psoralen plus ultraviolet A for psoriasis. Acta Derm Venereol. 2008;88(6):589-593.
45. Yentzer BA, Yelverton CB, Pearce DJ, et al. Adherence to acitretin and home narrowband ultraviolet B phototherapy in patients with psoriasis. J Am Acad Dermatol. 2008;59(4):577-581.
46. Carlin CS, Callis KP, Krueger GG. Efficacy of acitretin and commercial tanning bed therapy for psoriasis. Arch Dermatol. 2003;139(4):436-442. (Pubitemid 36427607)
47. Katz HI, Waalen J, Leach EE. Acitretin in psoriasis: An overview of adverse effects. J Am Acad Dermatol. 1999;41(3 Pt 2):7S-12S.
48. Lacour M, Mehta-Nikhar B, Atherton DJ, et al. An appraisal of acitretin therapy in children with inherited disorders of keratinization. Br J Dermatol. 1996;134(6):1023-1029. (Pubitemid 26183134)
49. Zhang XB, Luo Q, Li CX, et al. Clinical investigation of acitretin in children with severe inherited keratinization disorders in China. J Dermatolog Treat. 2008;19(4):221-228.
50. Traupe H. The Ichthyoses. A Guide to Clinical Diagnosis, Genetic Counseling and Therapy. Berlin: Springer-Verlag; 1989.
51. Capella GL, Fracchiolla C, Frigerio E, et al. A controlled study of comparative efficacy of oral retinoids and topical betamethasone/salicylic acid for chronic hyperkeratotic palmoplantar dermatitis. J Dermatolog Treat. 2004;15(2):88-93. (Pubitemid 38477944)
52. Thestrup-Pedersen K, Andersen KE, Menne T, et al. Treatment of hyperkeratotic dermatitis of the palms (eczema keratoticum) with oral acitretin. A single-blind placebo-controlled study. Acta Derm Venereol. 2001;81(5):353-355. (Pubitemid 34019180)
53. Gaeta GM, Gombos F, Femiano F, et al. Acitretin and treatment of the oral leucoplakias. A model to have an active molecules release. J Eur Acad Dermatol Venereol. 2000;14(6):473-478. (Pubitemid 32899270)
54. Bousema MT, Romppanen U, Geiger JM, et al. Acitretin in the treatment of severe lichen sclerosus et atrophicus of the vulva: A double-blind, placebo-controlled study. J Am Acad Dermatol. 1994;30(2 Pt 1):225-231. (Pubitemid 24051887)
55. Laurberg G, Geiger JM, Hjorth N, et al. Treatment of lichen planus with acitretin. A double-blind, placebo-controlled study in 65 patients. J Am Acad Dermatol. 1991;24(3):434-437.
56. Schroder K, Zaun H, Holzmann H, et al. Pustulosis palmo-plantaris. Clinical and histological changes during etretin (acitretin) therapy. Acta Derm Venereol Suppl (Stockh). 1989;146:111-116. (Pubitemid 20013759)
57. Canpolat F, Akpinar H, Cemil BC, et al. A case of subcorneal pustular dermatosis in association with monoclonal IgA gammopathy successfully treated with acitretin. J Dermatolog Treat. 2010;21(2):114-416.
58. Yayli S, Bahadir S, Alpay K, et al. A case of juvenile subcorneal pustular dermatosis successfully treated with acitretin. Int J Dermatol. 2006;45(9):1131-1133. (Pubitemid 44317152)
59. Marliere V, Beylot-Barry M, Beylot C, et al. Successful treatment of subcorneal pustular dermatosis (Sneddon-wilkinson disease) by acitretin: Report of a case. Dermatology. 1999;199(2):153-155. (Pubitemid 29494792)
60. Herbst RA, Vogelbruch M, Ehnis A, et al. Combined ultraviolet A1 radiation and acitretin therapy as a treatment option for pityriasis rubra pilaris. Br J Dermatol. 2000;142(3):574-575. (Pubitemid 30159099)
61. Ruzicka T, Sommerburg C, Goerz G, et al. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol. 1992;127(5):513-518.
62. Bavinck JN, Tieben LM, Van der Woude FJ, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: A double-blind, placebo-controlled study. J Clin Oncol. 1995;13(8):1933-1938.
63. McKenna DB, Murphy GM. Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br J Dermatol. 1999;140(4):656-660. (Pubitemid 29191384)
64. De Sevaux RG, Smit JV, De Jong EM, et al. Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: Clinical effects of a randomized trial comparing two doses of acitretin. J Am Acad Dermatol. 2003;49(3):407-412. (Pubitemid 37051901)
65. Smit JV, De Sevaux RG, Blokx WA, et al. Acitretin treatment in (pre)malignant skin disorders of renal transplant recipients: Histologic and immunohistochemical effects. J Am Acad Dermatol. 2004;50(2):189-196. (Pubitemid 38174273)
66. George R, Weightman W, Russ GR, et al. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australas J Dermatol. 2002;43(4):269-273. (Pubitemid 35365416)
67. Pilkington T, Brogden RN. Acitretin. A review of its pharmacology and therapeutic use. Drugs. 1992;43(4):597-627.
68. Vahlquist C, Olsson AG, Lindholm A, et al. Effects of gemfibrozil (Lopid) on hyperlipidemia in acitretin-treated patients. Results of a double-blind cross-over study. Acta Derm Venereol. 1995;75(5):377-380.
69. Roenigk HH, Jr., Callen JP, Guzzo CA, et al. Effects of acitretin on the liver. J Am Acad Dermatol. 1999;41(4):584-588. (Pubitemid 29480409)
70. Kreiss C, Amin S, Nalesnik MA, et al. Severe cholestatic hepatitis in a patient taking acitretin. Am J Gastroenterol. 2002;97(3):775-777. (Pubitemid 34245928)
71. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451-485.
72. Maradit H, Geiger JM. Potential risk of birth defects after acitretin discontinuation. Dermatology. 1999;198(1):3-4. (Pubitemid 29086326)
73. Katugampola RP, Finlay AY. Oral retinoid therapy for disorders of keratinization: Single-centre retrospective 25 years' experience on 23 patients. Br J Dermatol. 2006;154(2):267-276. (Pubitemid 43382697)
74. Halverstam CP, Zeichner J, Lebwohl M. Lack of significant skeletal changes after long-term, low-dose retinoid therapy: Case report and review of the literature. J Cutan Med Surg. 2006;10(6):291-299. (Pubitemid 351517512)
75. Beyer V, Wolverton SE. Recent trends in systemic psoriasis treatment costs. Arch Dermatol. 2010;146(1):46-54.
76. Lebwohl M, Drake L, Menter A, et al. Consensus conference: Acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol. 2001;45(4):544-553. (Pubitemid 32917249)
77. Yentzer BA, Feldman SR. Tanning beds as an alternative for psoriasis when office-based phototherapy is not accessible. J Dermatolog Treat. 2009;20(4):238-240.
78. Su J, Pearce DJ, Feldman SR. The role of commercial tanning beds and ultraviolet A light in the treatment of psoriasis. J Dermatolog Treat. 2005;16(5-6):324-326. (Pubitemid 43170203)
79. Fleischer AB, Jr., Clark AR, Rapp SR, et al. Commercial tanning bed treatment is an effective psoriasis treatment: Results from an uncontrolled clinical trial. J Invest Dermatol. 1997;109(2):170-174. (Pubitemid 27337331)